Arterial duct redilatation/restenting: a single center experience

Santoro G. (1), Gaio G. (1), Palladino MT. (1), Sorrentino R. (1), Pignatiello M. (1), Caianiello G. (2), Russo MG. (1)
AORN dei Colli, Monaldi Hospital, Second University of Naples, Pediatric Cardiology (1)
AORN dei Colli, Monaldi Hospital, Second University of Naples, Pediatric Cardiac Surgery (2)

BACKGROUND. Maintaining arterial duct (AD) patency is widely considered an effective alternative to surgical systemic-to-pulmonary artery shunt in neonates with congenital heart disease and duct-dependent pulmonary circulation (CHD-DDPC). Re-dilatation/re-stenting is sometimes needed due to progressive flow reduction secondary to patients growth and/or intra-stent re-stenosis.

METHODS. Aim of the study is to evaluate safety and feasibility of re-dilatation/re-stenting procedure compared to primary procedure. Between April 2003 and October 2011, 91 neonates underwent attempt of AD stenting as palliation of CHD-DDPC at our Institution (Group I). Among them, 15 patients needed a second procedure of re-dilatation/re-stenting (Group II).

RESULTS. Procedure was successfully completed in all patients in Group II (100%) versus 85/91 patients of the Group I (93.5%). Twelve patients underwent ductal re-stenting, 2 patients ductal re-dilatation, after 4.8 ± 2.6 months from the first procedure. After re-stenting/re-dilatation the duct size increased from 2.2±1.4 to 3.3±0.5 mm (p<0.01, p=NS vs Group I) and percutaneous O2 saturation increased from 75+4 to 93+5% (p<0.0001; p=NS vs Group I). Life-threatening complications and need for emergency surgical shunt was recorded in 2/14 group II pts (13% vs 1.1 % in Group I) due to acute stent thrombosis after deployment in both patients. In-hospital procedural-related mortality was 6.6% in group II vs 1.1 % in group I.

CONCLUSIONS. AD re-stenting/re-dilatation is a feasible mini-invasive palliation of CDH-DDPC supporting clinical improvement. Acute thrombosis is a life-threatening major complications most frequently recorded in the re-restenting procedure. Early and clinical symptomatic stent occlusion seems to be a risk factor. Probably a more aggressive anti-platelet therapy could be necessary in this subgroup of patients.